Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura

Research output: Contribution to journalArticlepeer-review


The hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are rare diseases that manifest with thrombocytopenia and microangiopathic hemolytic anemia accompanied by renal and neurologic dysfunction. Most childhood cases of HUS are caused by Shiga-toxin-producing bacteria and have a good prognosis. The other form, atypical HUS (aHUS), accounts for 10% of cases. Prognosis of aHUS and TTP has changed over time from fatal disorders to 60% to 80% survival in the plasma therapy era. In the past 10 years the molecular bases of aHUS and TTP have been discovered that mostly lead to uncontrolled activation of the complement system in aHUS and to abnormal von Willebrand factor processing in TTP. Identification of the underlying abnormality in an individual patient can provide prognostically significant information in predicting long-term outcome, response to therapies, and transplant outcome. It also paves the way for the use of specific new therapies in the near future.

Original languageEnglish
Pages (from-to)395-408
Number of pages14
JournalSeminars in Nephrology
Issue number4
Publication statusPublished - Jul 2010


  • ADAMTS13
  • Complement
  • Hemolytic uremic syndrome
  • Thrombotic thrombocytopenic purpura

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this